D. Berd

发表

Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.

C. Shields, J. Shields, I. Chervoneva, 2015, Journal of vascular and interventional radiology : JVIR.

The importance of tamoxifen to a cisplatin‐containing regimen in the treatment of metastatic melanoma

M. Mastrangelo, J. Sprandio, R. Bellet, 1989, Cancer.

Current concepts of the biology of human cutaneous malignant melanoma.

W. Clark, E. A. Bernardino, M. Mastrangelo, 1977, Advances in cancer research.

A pilot study of low-dose thalidomide and interferon &agr;-2b in patients with metastatic melanoma who failed prior treatment

Takami Sato, M. Mastrangelo, D. Berd, 2007, Melanoma research.

Gene therapy for human cancer: an essay for clinicians.

F. Nathan, M. Mastrangelo, E. Lattime, 1996, Seminars in oncology.

Cellular vaccine therapies for cancer.

H. Maguire, Takami Sato, M. Mastrangelo, 1998, Cancer treatment and research.

Melanoma and vitiligo: immunology’s Grecian urn

H. Maguire, Takami Sato, M. Mastrangelo, 1996, Cancer Immunology, Immunotherapy.

Long‐term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy

J. Bertino, R. Deconti, J. Cornog, 1975, Cancer.

TCR Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl-Modified Vaccine1

Takami Sato, M. Mastrangelo, D. Berd, 2002, The Journal of Immunology.

Dinitrophenyl-Modified Vaccine Administration of Autologous Infiltrating Melanoma Metastases After TCR Rearrangement in Lymphocytes

Takami Sato, M. Mastrangelo, D. Berd, 2002 .

Interleukin 10 production by human melanoma.

P. McCue, Takami Sato, M. Mastrangelo, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

Takami Sato, M. Mastrangelo, D. Berd, 2002, Cancer Immunology, Immunotherapy.

A Study of Antitumor (Phase II) and Immunosuppressive Effects of ICRF‐159 in Patients with Metastatic Melanoma

M. Mastrangelo, R. Bellet, R. Catalano, 1976, Journal of clinical pharmacology.

Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.

L. Eisenlohr, T. N. Bullock, M. Mastrangelo, 1997, Clinical immunology and immunopathology.

Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential

Takami Sato, M. Terai, M. Mastrangelo, 2009, Cancer Immunology, Immunotherapy.

Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy

R. Yasuda, Takami Sato, M. Terai, 2003, Cancer Immunology, Immunotherapy.

Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.

M. Mastrangelo, R. Bellet, R. Catalano, 1978, Medical and pediatric oncology.

Paclitaxel and tamoxifen

Takami Sato, F. Nathan, M. Mastrangelo, 2000, Cancer.

Effects of Corynebacterium parvum on immunity

D. Berd, 1978 .

Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice.

D. Berd, M. Mitchell, 1976, Cancer research.

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma

Takami Sato, M. Eto, M. Terai, 2012, Cancer Immunology, Immunotherapy.

Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.

M. Mastrangelo, R. Bellet, E. McClay, 1987, Cancer treatment reports.

High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

C. Shields, J. Shields, I. Chervoneva, 2009, Radiology.

Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study

C. Shields, J. Shields, K. Patel, 2005, Melanoma research.

Expression of cytokine mRNA in human melanoma tissues

O. Bagasra, M. Mastrangelo, E. Lattime, 1995, Cancer Immunology and Immunotherapy.

Development of antibodies to granulocyte-macrophage colony stimulationg factor (GM-CSF) after embolization of the hepatic artery with GM-CSF

D. Eschelman, Takami Sato, M. Terai, 2005 .

Protracted survival after resection of metastatic uveal melanoma

J. Shields, Takami Sato, F. Nathan, 2000, Cancer.

Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma

T. Hyslop, A. Berger, Takami Sato, 2012, Journal of surgical oncology.

Effect of 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1 -nitrosourea Adjuvant Therapy on the Immune Response of Patients with Malignant Melanoma1

E. J. Wilson, M. Mastrangelo, R. Bellet, 2006 .

Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine.

H. Maguire, Takami Sato, M. Mastrangelo, 1995, Clinical immunology and immunopathology.

BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.

C. Shields, P. De Potter, F. Nathan, 1997, Journal of experimental & clinical cancer research : CR.

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine

I. Chervoneva, K. Patel, Takami Sato, 2011, Cancer Immunology, Immunotherapy.

Peritoneal macrophage response to leukemia L1210 in syngeneic mice.

D. Berd, R. Prehn, 1977, Journal of the National Cancer Institute.

Calculation of survival of patients with stage III melanoma.

Takami Sato, M. Mastrangelo, D. Berd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.

C. Shields, J. Shields, I. Chervoneva, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Active specific immunization in the treatment of patients with melanoma.

H. Maguire, F. Nathan, M. Mastrangelo, 1996, Seminars in oncology.

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

H. Maguire, Takami Sato, D. Berd, 2001, International journal of cancer.

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

G. Murphy, H. Maguire, G. Murphy, 1991, Cancer research.

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

D. Berd, M. Mastrangelo, D. Berd, 1988, Cancer research.

Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens.

M. Herlyn, H. Koprowski, D. Berd, 1989, Cancer research.

Phase II trial of VM-26 in patients with metastatic malignant melanoma.

M. Mastrangelo, R. Bellet, D. Berd, 1978, Cancer treatment reports.

Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency.

G. Murphy, R. Korngold, P. McCue, 1991, Cancer research.

Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

C. Farina, A. Anichini, G. Parmiani, 1998, Journal of immunotherapy.

Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.

Ashutosh Kumar Singh, C. Shields, C. Croce, 1994, Cancer research.

A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma.

M. Grever, F. Davidorf, J. Gamel, 1990, American journal of ophthalmology.